Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by NewToInvesting7on Aug 17, 2021 3:19pm
234 Views
Post# 33718165

Few Questions

Few QuestionsFirst of all, I should say that I am disappointed at the significant drop in Covid testing revenues, especially since Stage added Rexall as a distributor of the test kits.  Would have thought it would be at least $1m. 

That said, I am still hopefully that the incoming members of the board, and the new CFO/COO will bring some much needed energy, strategy and goal execution for StageZero. 

What I want to see StageZero follow through on with frequent NRs releases, relate to the following:

1.  Completion of Care acquisition.
2.  Announcement of first AVRT/Aristotle revenues.
3.  Announcement of new partnerships that are currently not part of Care/HC.
4.  Announcement of ANY buy-out offers, regardless of whether the CEO thinks the offer is too low.
5.  Success stories of partnerships they converted from Covid testing to AVRT/Aristotle testing.

I can add more, like "is SEEK going to be an active partnership?", but sadly am too lazy to type right now.

https://seekacure.com/


Cheers!
   
<< Previous
Bullboard Posts
Next >>